Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,283 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06838845Recruiting
A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Guangzhou, GuangdongAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06846320RecruitingPhase 2
Study of ABBV-932 for generalized anxiety disorder
This trial tests an oral medicine called ABBV-932 when added to current antidepressant therapy for people with generalized anxiety disorder (GAD) who still have symptoms. It aims to see if the combination can improve anxiety and reduce side effects.
Huntsville, AlabamaAges 18–65 - NCT06839131RecruitingPhase 1
Study of SPH9788 tablets in healthy Chinese volunteers
This trial tests a new medicine called SPH9788 in healthy people to see how the body handles it. Volunteers must be generally healthy and follow lifestyle rules to help researchers understand the drug's safety and effects.
ShanghaiAges 18–45 - NCT06839053RecruitingPhase 2
Study of sonrotoclax, rituximab, and zanubrutinib for CLL, SLL, and MCL
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Seattle, WashingtonAges 18 years+ - NCT06830759Recruiting
Real-world study of epcoritamab for lymphoma
This study looks at how well epcoritamab works for people with diffuse large B-cell lymphoma or follicular lymphoma who have already tried two or more treatments. Researchers want to see how it works in routine care, not in a strict research setting.
Ciudad Autonoma de Buenos Aire, Buenos AiresAges 18 years+ - NCT06832410RecruitingPhase 3
Testing VX-880 for type 1 diabetes with a kidney transplant
This trial tests a new treatment called VX-880 for people who have had type 1 diabetes for at least 5 years and have already received a kidney transplant. The goal is to see if VX-880 can improve blood sugar control while you continue your current transplant medications.
Philadelphia, PennsylvaniaAges 18–65 - NCT06827613RecruitingPhase 1/Phase 2
Study of invikafusp alfa plus sacituzumab govitecan for advanced solid tumors
This trial tests a new drug combination for people with advanced breast cancer (triple-negative or hormone receptor-positive). The goal is to see if the combination helps shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06830798RecruitingPhase 3
Ravulizumab to prevent delayed graft function after kidney transplant
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Phoenix, ArizonaAges 18 years+ - NCT06830343RecruitingPhase 1
Safety study of SYH9017 for overweight and obesity
This study tests a new medication called SYH9017 for people who are overweight or have obesity. It aims to see how safe the drug is, how well it is tolerated, and how the body processes it. Participants will receive either the drug or a placebo and be monitored closely.
Beijing, Beijing MunicipalityAges 18–60 - NCT06826612RecruitingPhase 1/Phase 2
Gene therapy trial for early Huntington's disease
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
Boston, MassachusettsAges 25–65 - NCT06827366Recruiting
Lifestyle study for people at high risk of colorectal cancer
This study tests a lifestyle program for people who are at high risk for colorectal cancer but have not been diagnosed. The goal is to see if healthy changes can help lower your risk over one year.
Lyon, FranceAges 35–74 - NCT06816147Recruiting
HealthyW8: a weight-health study for adults 60+
This study tests a program to help people aged 60 and older in Luxembourg maintain a healthy weight using a smartphone app. It may be a good fit if you are generally healthy, not on a strict diet, and want to prevent weight gain as you age.
LuxembourgAges 60 years+ - NCT06822738RecruitingPhase 3
Study of XEN63 gel stent for glaucoma patients
This trial tests a new gel stent (XEN63) to lower eye pressure in adults with glaucoma. It compares two ways of putting the stent in the eye, and may help people who have not had success with other treatments.
Glendale, ArizonaAges 45 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Birmingham, AlabamaAges 18 years+ - NCT06824103RecruitingPhase 4
Study of ruxolitinib for chronic graft-versus-host disease in China
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hefei, AnhuiAges 12–100 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT06822426RecruitingPhase 3
Catheter lock solution to prevent bloodstream infections in patients on IV nutrition
This study tests a catheter lock solution called DefenCath (taurolidine and heparin) against a standard heparin lock to see if it reduces central line bloodstream infections in people receiving IV nutrition (total parenteral nutrition) for more than 3 months.
Los Angeles, CaliforniaAges 12 years+ - NCT06819735RecruitingPhase 1/Phase 2
Testing DT-7012 in Advanced Solid Tumors
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06818643RecruitingPhase 1/Phase 2
Study of MK-3120 for advanced solid tumors
This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT06815575RecruitingPhase 1
Study of RC220 with Doxorubicin for Advanced Solid Tumors
This trial tests a new drug called RC220 combined with the chemotherapy doxorubicin for people with advanced solid tumors that have not responded to prior treatments. The goal is to find a safe dose and see how the body handles the combination.
Gosford, New South WalesAges 18–80 - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced cancers
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT06820723RecruitingPhase 2
Testing a single dose of CYB003 for depression and anxiety
This trial tests a single dose of an investigational drug (CYB003) in people with depression and anxiety who haven't gotten enough help from their current antidepressant. You would take a psilocybin-like medication and be monitored for how it affects your mood and anxiety.
Columbus, OhioAges 21–65 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Homewood, AlabamaAges 55–90
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,283 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.